Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Schering-Plough 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Schering-Plough 3Q

Pharmaceutical sales in the quarter were $3.5 billion (+6%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough 3Q

3Q Revenues: $4.5 billion (-2%)

3Q Earnings: $515 million (-16%)

YTD Revenues: $13.5 billion (-4%)

YTD Earnings: $2.0 billion (+43%)

Comments: Pharmaceutical sales in the quarter were $3.5 billion (+6%). Sales of Remicade were up 8% to $608 million. Sales of Temodar were $278 million (+2%). Nasonex sales were up 3% to $266 million. Pegintron sales were down 16% to $198 million. Global sales of Clarinex were $164 million (-7%). Prescription Claritin sales were $95 million. Net sales of the cholesterol franchise, which include sales of the cholesterol joint venture plus sales recorded by S-P in non-joint venture territories (such as Japan and Latin America), were $1.1 billion (-5%). R&D expenses were $913 million in the quarter (+2%). For the quarter and YTD, results include $160 million gain on sales of certain divested animal health products associated with the OBS acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters